<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Prostate Cancer Prostatic Dis</journal-id><journal-id journal-id-type="iso-abbrev">Prostate Cancer Prostatic Dis</journal-id><journal-title-group><journal-title>Prostate Cancer and Prostatic Diseases</journal-title></journal-title-group><issn pub-type="ppub">1365-7852</issn><issn pub-type="epub">1476-5608</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38418892</article-id><article-id pub-id-type="pmc">PMC11349934</article-id>
<article-id pub-id-type="publisher-id">797</article-id><article-id pub-id-type="doi">10.1038/s41391-024-00797-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7021-968X</contrib-id><name><surname>Zorko</surname><given-names>Nicholas A.</given-names></name><address><email>zorko004@umn.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><bio><sec id="FPar1"><title>Nicholas Zorko</title><p id="Par1">is an Assistant Professor of Medicine at the University of Minnesota Masonic Cancer Center specializing in genitourinary oncology and cellular therapies. He treats a unique combination of patients consisting of both genitourinary oncology and bone marrow transplant/cellular therapy recipients. He completed his MD and PhD at The Ohio State University and his clinical residency and fellowship at the University of Minnesota. His translational laboratory focuses on the development of natural killer (NK) cell engager molecules and off-the-shelf, engineered NK cells to treat prostate cancer and other GU malignancies. He is a 2022 Prostate Cancer Foundation Young Investigator and the recipient of a United States Department of Defense Early Investigator Research Award. His clinical trial work includes several industry-sponsored Phase I immune engager and chimeric antigen receptor (CAR) T cell products to treat late-stage prostate cancers and other refractory solid tumors and a pending investigator-initiated NK cell engager trial. <inline-graphic xlink:href="41391_2024_797_Figa_HTML.gif" id="d33e227"/></p></sec></bio></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0008-2487-9079</contrib-id><name><surname>Makovec</surname><given-names>Allison</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Elliott</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kellen</surname><given-names>Samuel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lozada</surname><given-names>John R.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Arafa</surname><given-names>Ali T.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Felices</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shackelford</surname><given-names>Madison</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Barata</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9480-2626</contrib-id><name><surname>Zakharia</surname><given-names>Yousef</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8205-738X</contrib-id><name><surname>Narayan</surname><given-names>Vivek</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Stein</surname><given-names>Mark N.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Zarrabi</surname><given-names>Kevin K.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Patniak</surname><given-names>Akash</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Bilen</surname><given-names>Mehmet A.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Radovich</surname><given-names>Milan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sledge</surname><given-names>George</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>El-Deiry</surname><given-names>Wafik S.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1381-2713</contrib-id><name><surname>Heath</surname><given-names>Elisabeth I.</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Hoon</surname><given-names>Dave S. B.</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Nabhan</surname><given-names>Chadi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Jeffrey S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hwang</surname><given-names>Justin H.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0031-9655</contrib-id><name><surname>Antonarakis</surname><given-names>Emmanuel S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017zqws13</institution-id><institution-id institution-id-type="GRID">grid.17635.36</institution-id><institution-id institution-id-type="ISNI">0000000419368657</institution-id><institution>Masonic Cancer Center, </institution><institution>University of Minnesota-Twin Cities, </institution></institution-wrap>Minneapolis, MN USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04wh5hg83</institution-id><institution-id institution-id-type="GRID">grid.492659.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0492 4462</institution-id><institution>Caris Life Sciences, </institution></institution-wrap>Phoenix, AZ USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02kb97560</institution-id><institution-id institution-id-type="GRID">grid.473817.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0418 9795</institution-id><institution>University Hospital Seidman Cancer Center, </institution></institution-wrap>Cleveland, OH USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01jhe7086</institution-id><institution-id institution-id-type="ISNI">0000 0004 6085 5246</institution-id><institution>Holden Comprehensive Cancer Center, </institution></institution-wrap>Iowa City, IA USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00b30xv10</institution-id><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution>Abramson Cancer Center, </institution><institution>University of Pennsylvania, </institution></institution-wrap>Philadelphia, PA USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00hj8s172</institution-id><institution-id institution-id-type="GRID">grid.21729.3f</institution-id><institution-id institution-id-type="ISNI">0000000419368729</institution-id><institution>Herbert Irving Comprehensive Cancer Center, </institution><institution>Columbia University New York, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/010h6g454</institution-id><institution-id institution-id-type="GRID">grid.415231.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0577 7855</institution-id><institution>Sidney Kimmel Cancer Center, </institution><institution>Jefferson Medical College, </institution></institution-wrap>Philadelphia, PA USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042wftp98</institution-id><institution-id institution-id-type="ISNI">0000 0004 0502 5207</institution-id><institution>University of Chicago Medicine Comprehensive Cancer Center, </institution></institution-wrap>Chicago, IL USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02gars961</institution-id><institution-id institution-id-type="ISNI">0000 0004 0413 0929</institution-id><institution>Winship Cancer Institute of Emory University, </institution></institution-wrap>Atlanta, GA USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gq02987</institution-id><institution-id institution-id-type="GRID">grid.40263.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9094</institution-id><institution>Legorreta Cancer Center, </institution><institution>Brown University, </institution></institution-wrap>Providence, RI USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01070mq45</institution-id><institution-id institution-id-type="GRID">grid.254444.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 1456 7807</institution-id><institution>Karmanos Cancer Institute, </institution><institution>Wayne State University, </institution></institution-wrap>Detroit, MI USA </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01gcc9p15</institution-id><institution-id institution-id-type="GRID">grid.416507.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0450 0360</institution-id><institution>Saint John&#x02019;s Cancer Institute, </institution><institution>Saint John&#x02019;s Health Center PHS, </institution></institution-wrap>Santa Monica, CA USA </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>2</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>2</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>28</volume><issue>1</issue><fpage>129</fpage><lpage>137</lpage><history><date date-type="received"><day>8</day><month>10</month><year>2023</year></date><date date-type="rev-recd"><day>17</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par2">Natural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to evaluate NK cell infiltration into tumors to develop an improved understanding of which histologies may be most amenable to NK cell-based therapies currently in the developmental pipeline.</p></sec><sec><title>Methods</title><p id="Par3">DNA (targeted/whole-exome) and RNA (whole-transcriptome) sequencing was performed from tumors from 45 cancer types (<italic>N</italic>&#x02009;=&#x02009;90,916 for all cancers and <italic>N</italic>&#x02009;=&#x02009;3365 for prostate cancer) submitted to Caris Life Sciences. NK cell fractions and immune deconvolution were inferred from RNA-seq data using quanTIseq. Real-world overall survival (OS) and treatment status was determined and Kaplan&#x02013;Meier estimates were calculated. Statistical significance was determined using X<sup>2</sup> and Mann&#x02013;Whitney <italic>U</italic> tests, with corrections for multiple comparisons where appropriate.</p></sec><sec><title>Results</title><p id="Par4">In both a pan-tumor and prostate cancer (PCa)&#x000a0;-specific setting, we demonstrated that NK cells represent a substantial proportion of the total cellular infiltrate (median range 2&#x02013;9% for all tumors). Higher NK cell infiltration was associated with improved OS in 28 of 45 cancer types, including (PCa). NK cell infiltration was negatively correlated with common driver mutations and androgen receptor variants (<italic>AR-V7</italic>) in primary prostate biopsies, while positively correlated with negative immune regulators. Higher levels of NK cell infiltration were associated with patterns consistent with a compensatory anti-inflammatory response.</p></sec><sec><title>Conclusions</title><p id="Par5">Using the largest available dataset to date, we demonstrated that NK cells infiltrate a broad range of tumors, including both primary and metastatic PCa. NK cell infiltration is associated with improved PCa patient outcomes. This study demonstrates that NK cells are capable of trafficking to both primary and metastatic PCa and are a viable option for immunotherapy approaches moving forward. Future development of strategies to enhance tumor-infiltrating NK cell-mediated cytolytic activity and activation while limiting inhibitory pathways will be key.</p></sec></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Cancer therapy</kwd><kwd>Cancer genetics</kwd><kwd>Prognostic markers</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense (United States Department of Defense)</institution></institution-wrap></funding-source><award-id>W81XWH-22-1-0242</award-id><award-id>W81XWH2110255</award-id><award-id>W81XWH-20-1-0659</award-id><award-id>W81XWH-20-1-0535</award-id><award-id>W81XWH-21-1-0255</award-id><award-id>W81XWH-20-1-0341</award-id><award-id>W81XWH2110255</award-id><award-id>W81XWH-20-1-0659</award-id><principal-award-recipient><name><surname>Zorko</surname><given-names>Nicholas A.</given-names></name><name><surname>Felices</surname><given-names>Martin</given-names></name><name><surname>Miller</surname><given-names>Jeffrey S.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000892</institution-id><institution>Prostate Cancer Foundation (PCF)</institution></institution-wrap></funding-source><award-id>22YOUN08</award-id><principal-award-recipient><name><surname>Zorko</surname><given-names>Nicholas A.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000002</institution-id><institution>U.S. Department of Health &#x00026; Human Services | National Institutes of Health (NIH)</institution></institution-wrap></funding-source><award-id>T32 GM008244</award-id><award-id>T32 GM008244</award-id><principal-award-recipient><name><surname>Zorko</surname><given-names>Nicholas A.</given-names></name><name><surname>Lozada</surname><given-names>John R.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100001422</institution-id><institution>American Society of Hematology (ASH)</institution></institution-wrap></funding-source><award-id>Medical Student Minority Award</award-id><principal-award-recipient><name><surname>Zorko</surname><given-names>Nicholas A.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100013187</institution-id><institution>Randy Shaver Cancer Research and Community Fund (Randy Shaver Cancer Research &#x00026; Community Fund)</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000054</institution-id><institution>U.S. Department of Health &#x00026; Human Services | NIH | National Cancer Institute (NCI)</institution></institution-wrap></funding-source><award-id>R35 CA283892</award-id><award-id>P01 CA111412</award-id><award-id>P30 CA077598</award-id><award-id>P01 CA111412</award-id><award-id>P01 CA065493</award-id><award-id>R35 CA283892</award-id><award-id>P01 CA065493</award-id><award-id>P01 CA111412</award-id><award-id>P30 CA077598</award-id><award-id>P30 CA077598</award-id><principal-award-recipient><name><surname>Zorko</surname><given-names>Nicholas A.</given-names></name><name><surname>Felices</surname><given-names>Martin</given-names></name><name><surname>Miller</surname><given-names>Jeffrey S.</given-names></name><name><surname>Antonarakis</surname><given-names>Emmanuel S.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par6">Metastatic castration-resistant prostate cancer (mCRPC) remains a significant burden and a leading cause of death for men in the United States and throughout the world. While there has been significant interest in harnessing the immune system to treat mCRPC [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>], only a small proportion of patients derive a benefit. Currently approved immunotherapies include Sipuleucel-T [<xref ref-type="bibr" rid="CR4">4</xref>] and pembrolizumab, which is approved for only a narrow subset of patients with tumor mutation burden high features or microsatellite instability (~3&#x02013;5% of mCRPC patients) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Attempts using other immune checkpoint inhibitors in isolation and in combination have had mixed results in small subsets of patients and remains under exploration [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. There remains an urgent need to develop immune and cellular-based therapies that are both efficacious and applicable to a broader population. Numerous T cell products have been either developed or are under development for mCRPC, including chimeric antigen receptor (CAR) T cells and T cell engagers as reviewed by Zarrabi et al. [<xref ref-type="bibr" rid="CR12">12</xref>]. Similar products are under development utilizing natural killer (NK) or NK-T cells as the effectors [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>] as previously reviewed by our group [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par7">Natural killer cells are cytotoxic lymphocytes which are part of the innate immune system and are capable of destroying malignant and virally-infected cells without the need for priming as is required by T cells [<xref ref-type="bibr" rid="CR17">17</xref>]. Circulating NK cells comprise between 5 and 20% of lymphocytes and the vast majority are phenotypically-defined by the presence of the surface marker CD56 and absence of CD3 (CD56+/CD3&#x02212;) with variable CD16 expression depending on developmental stage. Notably, there are subsets of CD56 negative NK cells [<xref ref-type="bibr" rid="CR18">18</xref>], which are missed by conventional analysis for this marker and has led to the proposal of alternative markers such as NKp46 and NKp30 [<xref ref-type="bibr" rid="CR19">19</xref>]. NK cells are not antigen-specific [<xref ref-type="bibr" rid="CR20">20</xref>]; however, NK cells can be redirected with CARs [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] or via immune engagers/monoclonal antibodies to induce antibody-dependent cellular cytotoxicity (ADCC) [<xref ref-type="bibr" rid="CR23">23</xref>]. In contrast to T cell-derived immune therapies, NK cell approaches allow for use of allogeneic (off-the-shelf) products, do not cause graft-versus-host disease, and have considerably lower risk for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) [<xref ref-type="bibr" rid="CR24">24</xref>]. Due to these key characteristics, development of NK cell products and strategies to overcome dysfunction are of increasing interest [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par8">No prior studies have delved into the influence of tumor-intrinsic mutational and gene expression profiles [<xref ref-type="bibr" rid="CR26">26</xref>] associated with NK cell infiltration and the association with outcomes with standard-of-care (SOC) therapies used for treatment of PCa. Using the largest collection of PCa samples with comprehensive molecular profiling of DNA and RNA (<italic>n</italic>&#x02009;=&#x02009;3365) from a database of real-world patient samples, we sought to evaluate whether NK cells infiltrate into PCa, to explore effects of NK cell infiltration on patient outcomes, and to understand tumor features affecting NK cell infiltration.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Specimens</title><p id="Par9">We retrospectively reviewed molecular alterations and related survival outcomes of <italic>N</italic>&#x02009;=&#x02009;90,916 for all cancers and <italic>N</italic>&#x02009;=&#x02009;3365 for PCa. Comprehensive molecular profiling, including whole-exome sequencing (WES) and whole transcriptome sequencing (WTS), was performed in a CLIA/CAP/ISO15189 certified clinical laboratory (Caris Life Sciences, Phoenix, AZ, USA) [<xref ref-type="bibr" rid="CR27">27</xref>]. This study was conducted in accordance with the guidelines of the Declaration of Helsinki, Belmont Report, and U.S. Common Rule. In keeping with 45 CFR 46.101(b)(4), this study was performed by using retrospective and deidentified clinical data. Therefore, this study was considered institutional review board exempt, and no patient consent was necessary.</p></sec><sec id="Sec4"><title>Survival analysis</title><p id="Par10">Real-world evidence (RWE) outcomes were assessed from insurance claims data. RWE overall survival (OS) was defined as time of treatment initiation date to either death or last contact in the insurance claims repository. As previously reported, patient death was assumed for any patient without a claim for more than 100 days, which holds true for more than 95% of patients with a recorded death in the NDI (National Death Index). Cox proportional hazard ratios were calculated for each comparison group and significance was determined as <italic>p</italic> values of &#x0003c;0.05 using the log-rank statistic.</p></sec><sec id="Sec5"><title>DNA Next-generation sequencing (NGS)</title><p id="Par11">Direct sequence analysis was conducted on genomic DNA isolated from microdissected, formalin-fixed, paraffin-embedded tumor samples using the NextSeq platform (Illumina, Inc., San Diego, CA) for 592 cancer-relevant genes [<xref ref-type="bibr" rid="CR28">28</xref>] or the Illumina Novaseq 6000 platform for whole exome sequencing (WES). For WES, a hybrid pulldown of baits designed to enrich for 720 clinically relevant genes at high coverage and high read-depth was used, along with another panel designed to enrich for an additional &#x0003e;20k genes at a lower depth and a 500&#x02009;Mb SNP backbone panel (Agilent Technologies) to help with gene amplification/deletion detection as previously described [<xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec6"><title>RNA whole transcriptome sequencing (WTS)</title><p id="Par12">Qiagen RNA FFPE tissue extraction kit was used for extraction. RNA quality and quantity were determined using the Agilent TapeStation (Agilent TapeStation Laptop, RRID:SCR_019547). Biotinylated RNA baits were hybridized to the synthesized and purified cDNA targets, and the bait&#x02013;target complexes were amplified in a post-capture PCR reaction. The Illumina NovaSeq 6500 was used to sequence the whole transcriptome from patients to an average of 60&#x02009;M reads. Raw data was demultiplexed by the Illumina Dragen BioIT accelerator, trimmed, counted, removed of PCR-duplicates, and aligned to human reference genome hg19 by the STAR aligner. For transcription counting, transcripts per million molecules were generated using the Salmon expression [<xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec7"><title>Immune cell infiltration</title><p id="Par13">To examine the associations with NK cells in PCa patients, NK cell tumor infiltration was inferred using quanTIseq, a computational method for quantifying immune cell fractions by deconvolution of bulk RNA-seq data [<xref ref-type="bibr" rid="CR29">29</xref>]. NK cell infiltration was assessed in 90,916 tumor biopsies across 45 distinct tumor types, including 3365 PCa patients.</p></sec><sec id="Sec8"><title>Statistical analyses</title><p id="Par14">Statistical significance was determined using X<sup>2</sup> and Mann&#x02013;Whitney <italic>U</italic> tests with corrections for multiple comparisons (Benjamini-Hochberg) where appropriate.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Characterization of NK cell fractions in PCa</title><p id="Par15">NK cell infiltration was assessed in 90,916 tumor biopsies across 45 distinct tumor types, including 3,365 PCa patients. Median NK cell fraction by tumor type ranged from a high of 7&#x02013;9% (medulloblastoma and gliomas) to a low of 2% (thyroid and thymic cancers), with a pan-cancer median of 3.50% (95% CI 3.49&#x02013;3.51%) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1A</xref>). Based on these measurements, PCa had the 11th highest median NK cell fraction among the 45 cancer types examined (4.9%, 95% CI 4.8&#x02013;5.0%). Given that prostate tumors have distinct outcomes and molecular characteristics based on disease site, we also compared the distribution of NK cell fractions between PCa biopsies from prostate, and distant metastatic sites (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1B</xref>). In tumors from metastatic PCa (mPCa) sites, the NK cell fractions were lower (4.1%, 95% CI 4.0&#x02013;4.2%) compared to prostate biopsy samples. We also observed notable NK cell fractions upon partitioning the samples into common metastatic sites including the liver, bone, lymph node, lung, and bladder (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1C</xref>). Available demographic data for groups are included in Table&#x000a0;<xref rid="MOESM3" ref-type="media">S1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><title>Characterization of NK cells in tumors.</title><p><bold>A</bold> NK cell fraction as a percentage of all cells calculated using quanTiseq for immune deconvolution using transcriptomic data. A total of 90,916 samples from 45 distinct tumor types were analyzed from a commercial database of real-world patient samples. Data shown in violin plots in which the white dot represents the median and the black box shows the ends of the first and third quartiles. <italic>p</italic> * &#x0003c; 0.05, ** &#x0003c; 0.01, *** &#x0003c; 0.001, **** &#x0003c; 0.0001. <bold>B</bold> Distribution of quanTIseq NK cell score across PCa tumors from the prostate and metastatic PCa tumors. Vertical dotted lines represent the median NK cell fraction for each subgroup. <bold>C</bold> Metastasis was then divided by anatomical sites, including liver and bone. Cohorts shown are stratified by the median NK cell fraction. Distribution of NK cell scores shown in violin plots in which the boundary of the violin represents the range of all data points.</p></caption><graphic xlink:href="41391_2024_797_Fig1_HTML" id="d33e697"/></fig></p></sec><sec id="Sec11"><title>NK cell profiles are associated with overall clinical outcomes and treatment regimen</title><p id="Par16">Within each cancer type, we stratified samples into NK cell-low and -high subgroups (&#x0003c;50th vs &#x0003e;50th percentile, respectively). For 28 of 45 cancer types that we examined, high levels of NK cell fractions were associated with improved OS (HR for individual tumor types ranging from 0.28&#x02013;0.84, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), while 16 of 45 cancer types (including low-grade glioma, GIST, and thyroid cancers) had HR&#x02009;&#x0003c;&#x02009;1.0 (range from 0.264&#x02013;0.997) with 95% CI crossing 1.0 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2A</xref>). Among all PCa patients, NK cell-high tumors were associated with significantly improved OS (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2B</xref>, HR 0.64, 95% CI 0.57&#x02013;0.71, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.00001). We further stratified the PCa patients by NK cell fraction quartiles to assess more granular associations with clinical outcomes. Increased NK cell fractions were associated with improved OS in PCa patients who had undergone primary prostate biopsy (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2C</xref>). However, NK cell infiltrates were not associated with statistically significant differences in outcomes regardless of metastatic biopsy site (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2D</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>NK cell profiles association with OS.</title><p><bold>A</bold> Association of overall survival (OS) in tumors with top 75th percentile NK cell infiltration (relative to all cancers) across 45 different tumor types. Dotted line represents the Hazard Ratio of 1.0. <italic>p</italic> * &#x0003c; 0.05, ** &#x0003c; 0.01, *** &#x0003c; 0.001, **** &#x0003c; 0.0001. <bold>B</bold> Progression-free survival (PFS) of patients with high (&#x0003e;= median) NK infiltration compared to low (&#x0003c;median) NK infiltration in 45 distinct tumor types. <bold>C</bold> OS of patients with tumors from the prostate and metastasis were partitioned into 4 quartiles as defined by the relative NK cell abundance. <bold>D</bold> OS for metastasis was further divided by common anatomical metastatic sites, including liver and bone. Cox proportional hazard ratios were calculated for each comparison group with significance determined as <italic>p</italic> values of &#x0003c;0.05 using log-rank statistics.</p></caption><graphic xlink:href="41391_2024_797_Fig2_HTML" id="d33e746"/></fig></p><p id="Par17">Interestingly, biopsies derived from the prostate with high NK fractions exhibited improved outcomes when treated with ADT (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), there was no significant difference in OS from the start of treatment among patients with metastatic biopsy samples (Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S1A</xref>), but no association with docetaxel (Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S1B</xref>). Similar to outcomes of patients treated with ADT, we observed that high levels of NK cell infiltrates were significantly associated with anti-PD(L)1 response (<italic>p</italic>&#x02009;=&#x02009;0.04) in samples derived from the prostate (Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S1C</xref>).</p></sec><sec id="Sec12"><title>The interaction of NK cell profiles with driver mutations in PCa</title><p id="Par18">To understand how NK cells may be associated with specific drivers or pathogenic mutations in PCa, we compared the mutation and mRNA expression profiles of NK cell-low (Q1) and -high (Q4) populations. Recurrent genomic alterations in <italic>RB1</italic>, <italic>TP53</italic>, and <italic>PTEN</italic> are associated with advanced metastatic PCa and poor prognosis [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. For both prostate and metastatic biopsies, we observed significantly lower <italic>RB1</italic>, <italic>TP53</italic>, and <italic>PTEN</italic> mutation frequencies in NK cell-high tumors relative to NK-low tumors (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3A</xref>). AR alterations, including genomic alterations, aberrant expression of splice variants (e.g. <italic>AR-V7</italic>), and genes that regulate AR signaling are key drivers of advanced PCa and poor hormonal responsivenness [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. Interestingly, we found that <italic>TMPRSS2-ERG</italic> fusions were significantly more common in NK cell-high tumors from both the prostate, but not metastatic biopsies. <italic>AR-V7</italic> expression was significantly decreased in NK cell-high tumors from prostate biopsies (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3B</xref>). Examining the expression of <italic>AR</italic> and <italic>AR</italic>-related signaling genes, we found that key targets such as <italic>KLK2</italic>, <italic>KLK3</italic>, <italic>STEAP2</italic>, and <italic>FOXA1</italic> demonstrated increased expression in NK-high samples even without increases in <italic>AR</italic> expression (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3C</xref>). Altogether, while <italic>AR</italic> transcriptional targets indicate activated AR signaling in NK cell high tumors, the activity was not consistently associated with higher levels of <italic>AR or AR-V7</italic>.<fig id="Fig3"><label>Fig. 3</label><caption><title>Interaction of NK cell profiles with driver mutations in PCa.</title><p>Pathogenic mutation frequency of common PCa drivers (<bold>A</bold>), median WTS (TPM) for AR associated genes (<bold>B</bold>), and pathogenic mutation frequency for AR associated genes (<bold>C</bold>) across NK cell high and low prostate and metastatic samples. <italic>p</italic> * &#x0003c; 0.05, ** &#x0003c; 0.01, *** &#x0003c; 0.001, **** &#x0003c; 0.0001. Cox proportional hazard ratios were calculated for each comparison group with significance determined as <italic>p</italic> values of &#x0003c;0.05 using log-rank statistics.</p></caption><graphic xlink:href="41391_2024_797_Fig3_HTML" id="d33e870"/></fig></p><p id="Par19">To analyze for effects in other signaling pathways, we conducted Gene Set Enrichment Anlaysis (GSEA) on the transcription profiles of the tumors either from the prostate, or metastatic sites [<xref ref-type="bibr" rid="CR33">33</xref>]. Overall, there were no Hallmark pathways enriched in the NK cell high samples, regardless of whether the sample was obtained from the prostate or a metastatic site. However, several pathways were enriched in the NK cell low samples, which was reflected in the negative Normalized Enrichment Scores (NES) (Table&#x000a0;<xref rid="MOESM4" ref-type="media">S2</xref>). We additionally included the differential expression profiles in Table&#x000a0;<xref rid="MOESM5" ref-type="media">S3</xref>. Of specific pathways that have been implicated in immune or tumor cell regulation, there was not enrichment of pathways that reflect cell cycle regulation, apoptosis, senescence, or proliferation. We found that the epithelial to mesenchymal transition (EMT) signature had a negative NES, and thus was enriched in NK low samples.</p></sec><sec id="Sec13"><title>NK cell abundance and current immune checkpoint inhibitor (ICI) targets</title><p id="Par20">To determine whether NK cell infiltrates are associated with these immunomodulatory receptors, we examined the expression levels of pro- and anti-inflammatory immune regulators in NK-high and -low prostate and metastatic PCa tumors (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). In biopsies from the prostate, high NK cell infiltration was associated with a significant increase in all analyzed target genes, including T cell-expressed costimulatory marker CD28 and professional antigen presenting cell-expressed second signals CD40 and CD80. There was concurrent and significantly increased expression of the immune checkpoint pathway markers <italic>HAVCR2</italic> (<italic>TIM-3</italic>), <italic>CTLA-4</italic>, <italic>PDCD1 (PD-1), PDCD1LG2 (PD-L1)</italic>, <italic>LAG3</italic>, and <italic>TIGIT</italic>, demonstrating increased immune suppressive signaling from both the tumor and immune cell populations. Metastatic biopsy samples had increased expression of <italic>PD-L1</italic>, <italic>CD28</italic>, and <italic>LAG3</italic> (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>NK cell association with current ICI targets.</title><p>Median WTS (TPM) for immune regulatory genes, some of which are immunotherapy targets, across NK cell high and low (<bold>A</bold>) prostate and (<bold>B</bold>) metastatic samples. <italic>p</italic> * &#x0003c; 0.05, ** &#x0003c; 0.01, *** &#x0003c; 0.001, **** &#x0003c; 0.0001. Cox proportional hazard ratios were calculated for each comparison group with significance determined as <italic>p</italic> values of &#x0003c;0.05 using log-rank statistics.</p></caption><graphic xlink:href="41391_2024_797_Fig4_HTML" id="d33e941"/></fig></p></sec><sec id="Sec14"><title>Interaction with other immune cells and chemokines</title><p id="Par21">We next characterized the TME composition of NK cell-high and -low samples. Primary prostate tumors with high NK cells had significantly increased B cell and M2 macrophage infiltration (1.4-fold increase, <italic>p</italic>-value&#x02009;&#x0003c;&#x02009;0.0001), while neutrophil infiltration was significantly decreased compared to NK cell-low tumors (2.8-fold decrease, <italic>p</italic>-value&#x02009;&#x0003c;&#x02009;0.0001) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). In PCa tumors from metastatic sites, there were similar increases in B cell and M2 macrophage counts in NK cell-high tumors (1.4-fold increase, <italic>q</italic>&#x02009;&#x0003c;&#x02009;0.0001 for both) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). Neutrophil infiltration was decreased in metastatic NK cell-high tumors as well, but to a lesser extent than tumors from the prostate (2.2-fold decrease, <italic>q</italic>&#x02009;&#x0003c;&#x02009;0.0001) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). NK cell-high tumors additionally had significant increases in myeloid dendritic cell infiltration in both primary PCa (10.87-fold increase, <italic>q</italic>&#x02009;&#x0003c;&#x02009;0.0001) and metastatic biopsy samples (1.38-fold increase, <italic>p</italic>-value&#x02009;&#x0003c;&#x02009;0.0001) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). Although the effects were greater in the prosatate samples, both NK cell-high PCa tumors from the prostate and metastatic sites exhibited significant association with the expression of a consistent set of chemokines including <italic>CCL19</italic> and CCL6 (Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">S2</xref>). <italic>CX3CL1</italic> and <italic>CXCL3</italic> were increased in primary prostate biopsies only (Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">S2</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><title>NK interaction with other Immune cells.</title><p><bold>A</bold> Immune cell deconvolution using quanTiseq demonstrates differences in cell fraction of B cells, macrophage M1/ M2, dendritic cells, neutrophils, T cell regulatory, and NK cells, as well as (<bold>B</bold>) monocytes, and T cells CD4/ CD8 in prostate and metastatic PCa tumors when comparing Q1 and Q4 NK cell infiltration groups. *<italic>p</italic>-values (**** &#x0003c; 0.0001).</p></caption><graphic xlink:href="41391_2024_797_Fig5_HTML" id="d33e1009"/></fig></p></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p id="Par22">In this study we present the largest compilation to our knowledge of whole exome and whole transcriptome analyses from PCa patients, consisting of 3365 PCa specimens. The prior largest datasets analyzed from The Cancer Genome Atlas (TCGA) contained 497 [<xref ref-type="bibr" rid="CR34">34</xref>] and 537 [<xref ref-type="bibr" rid="CR35">35</xref>] PCa samples, respectively. It is important to note that the vast majority of cancer samples within TCGA are pre-treatment primary prostate tumors, while our cohort is a mix of pre- and on-treatment samples obtained from the prostate and prevalent metastatic sites such as the liver and bone [<xref ref-type="bibr" rid="CR36">36</xref>]. Within PCa itself, we demonstrated robust infiltration of NK cell populations of approximately 5% of the total cell number. We further showed that PCa was among the top tumor types in terms of NK cell infiltration, pointing towards the possibility that NK cell therapies may be more useful than previously thought for this cancer type. Due to differences in output (percent of total cells [<xref ref-type="bibr" rid="CR35">35</xref>] and cell score [<xref ref-type="bibr" rid="CR34">34</xref>]), it is difficult to make direct comparisons between our study and those previously published.</p><p id="Par23">When we further stratified OS with the biopsy site, the upper quartile of NK cell infiltration was associated with statistically significant prolongation of survival for prostatic samples. No survival benefit was noted in patients from whom metastasic samples were sequenced. We then sought to evaluate whether the specific treatment regimen utilized had an effect upon overall survival based on quartiles of NK cell infiltration and biopsy site. Survival was improved in patients with upper quartile NK cell infiltration who underwent prostate biopsy and treatment with ADT. Note that we were not able to further stratify based on receipt of novel androgen receptor targeting (ART) versus conventional ADT.</p><p id="Par24">Significantly reduced NK cell infiltration was associated with the presence of known PCa driver mutations <italic>PTEN</italic>, <italic>RB1</italic>, or <italic>TP53</italic> in primary biopsy samples. We then focused on pathognomonic mutations associated with PCa and discovered that <italic>AR-V7</italic> variants were more frequently associated with lower NK cell infiltration, while good-prognosis <italic>TMPRSS2-ERG</italic> fusions [<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>] were associated with increased NK cell infiltration in primary prostate samples. Whether these associations with NK cell infiltration were driven by better prognosis at baseline or if there is a role for ADT in NK cell function and infiltration remain to be determined.</p><p id="Par25">In both primary prostate and metastatic biopsies, markers of immune stimulation/co-stimulation (<italic>CD28</italic>) and exhaustion (<italic>LAG3</italic> and <italic>PD-L1</italic>) were significantly increased in NK cell-high samples. While our evidence thus far points towards improved survival of patients with increased NK cell function, our analysis of these markers demonstrates that the NK cells that are infiltrating into the prostate are likely either exhausted or become quickly exhausted, further limiting their ability to destroy prostate cancer cells that they encounter. Of particular interest is the marked reduction in immunosuppressive neutrophils, M2 macrophages, and regulatory T cells, which is consistent with a compensatory regulatory mechanism counteracting increased inflammation induced by infiltrating NK cells [<xref ref-type="bibr" rid="CR41">41</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>]. Interestingly, CD4 and CD8 populations were not significantly associated with differences in NK cell infiltration.</p><p id="Par26">Finally, we sought to determine possible differences in chemokines that may be affecting NK cell infiltration into prostate tissue. Across both primary prostate and metastatic biopsies, <italic>CCL19</italic> and <italic>CXCL6</italic> were elevated in NK cell-high samples, while <italic>CCL5</italic>, <italic>CXCL1</italic> and <italic>CX3CL1</italic> were increased only in primary prostate biopsies. CCL19 is primarily a chemoattractant for activated CD56<sup>bright</sup> NK cells and does not induce cytotoxicity [<xref ref-type="bibr" rid="CR44">44</xref>]. CCL5 is typically associated with dendritic, T, and resting NK cell chemotaxis while augmenting NK cell cytolytic activity [<xref ref-type="bibr" rid="CR44">44</xref>]. This is in contrast to resting CD56<sup>dim</sup> NK cells which typically lack CC family chemokine receptors and would not be affected by CCL5 [<xref ref-type="bibr" rid="CR44">44</xref>]. CCL5 is a particularly important factor for stimulation of NK cell cytolytic activity and is produced by activated NK cells. CXCL1 is bound by CXCR2 and highly produced by neutrophils, while promoting trafficking of immune suppressive myeloid cells [<xref ref-type="bibr" rid="CR45">45</xref>]. Our associations strongly support the presence of chemokines that both attract NK cells to the PCa TME and induce NK activation.</p><p id="Par27">There are limitations to our study given the nature of the samples and bulk RNA sequencing methods used. While tissues were microdissected to enrich for tumor tissue, we are limited in describing the immune landscape of these tumor samples due to the use of bulk sequencing rather than single-cell (sc) RNA sequencing, although scRNA datasets remain somewhat limited in the number of samples analyzed [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Thus, the immune populations in this study are inferred based on gene expression signatures of the whole microdissected sample rather than from individual cells. Different methods for immune cell deconvolution of RNA-seq data have been utilized, with CIBERSORT [<xref ref-type="bibr" rid="CR48">48</xref>] being the most common method used in comparable studies and quanTIseq being used in ours [<xref ref-type="bibr" rid="CR29">29</xref>]. quanTIseq (quantification of the Tumor Immune contexture from human immune RNA-seq data) is a computational method that determines the abolute fractions of immune cells using unique bulk gene expression signatures based on 10 distinct immune cell types [<xref ref-type="bibr" rid="CR29">29</xref>]. Altought this is used on bulk WTS data, quanTIseq outputs have been validated compared to flow cytometry, immunohistochemistry, and multiple publicly available data sets [<xref ref-type="bibr" rid="CR29">29</xref>]. Direct comparisons between data produced from these two analytic tools (CIBERSORT versus quanTIseq) are difficult, but Finotello et al. [<xref ref-type="bibr" rid="CR49">49</xref>] did compare various immune deconvolution strategies to gold-standard FACS and immunohistochemistry. That study demonstrated an overall strong correlation between bulk RNA-seq data analyzed with immune deconvolution strategies and gold-standard analysis with typical r-values of &#x0003e;0.68 for macrophages/monocytes, NK cells and total CD4&#x02009;+&#x02009;T cells [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par28">Due to the nature of the biopsies collected, it is not possible to make inferences regarding associations with localized versus metastatic disease as well or include clinical features such as Gleason score due to the information included with our dataset, limiting further correlative analyses. In particular, prostate biopsies are not necessarily solely from patients with localized disease as the prostate may be biopsied even in metastatic cases; however, we can make inferences regarding metastatic disease alone.</p></sec><sec id="Sec16" sec-type="conclusion"><title>Conclusions</title><p id="Par29">We present here the largest study analyzing the immune environment and associated molecular features associated with NK cell infiltration in prostate adenocarcinoma, strongly supporting further development of NK cell therapies to treat prostate cancers. Strategies to reduce immune populations that suppress cytotoxic NK cells from infiltrating prostate cancer tissue are needed along with molecular markers or engagers to both promote NK cell infiltration and prevent NK cell exhaustion. These results point to the potential promise of NK cell therapies, including bi- and tri-specific immune engager molecules and CAR-NK, iNK-T therapies for the treatment of PCa.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41391_2024_797_MOESM1_ESM.pdf"><caption><p>Supplemental Figure 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41391_2024_797_MOESM2_ESM.pdf"><caption><p>Supplemental Figure 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41391_2024_797_MOESM3_ESM.xlsx"><caption><p>Supplemental Table 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41391_2024_797_MOESM4_ESM.xlsx"><caption><p>Supplemental Table 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41391_2024_797_MOESM5_ESM.xlsx"><caption><p>Supplemental Table 3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="41391_2024_797_MOESM6_ESM.docx"><caption><p>Supplemental Figure Legends</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Nicholas A. Zorko, Allison Makovec.</p></fn><fn><p>These authors jointly supervised this work: Justin H. Hwang, Emmanuel S. Antonarakis.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41391-024-00797-0.</p></sec><notes notes-type="author-contribution"><title>Author contributions</title><p>NAZ, AM, JHH and EAS conceptulizated and designed the study, analyzed data, drafted/revised manuscript, and approved of final manuscript. AE designed the study, acquired data, analyzed data, drafted/revised manuscript, and approved of final manuscript. SK, JRR, ATA, MF, MS, PB, YZ, VN, MNS, KKZ, MAB, MR, GS, WSE, EIH, DSBH, CH, JSM interpreted results, drafted/revised manuscript, and approved of final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding information</title><p>This work was funded by Caris Life Sciences and the Division of Hematology, Oncology and Transplantation, University of Minnesota. NAZ was supported by a Department of Defense Early Investigator Award (W81XWH-22-1-0242), a 2022 Prostate Cancer Foundation Young Investigator Award (22YOUN08), the University of Minnesota Institute for Prostate and Urologic Cancers Philanthropic Fund, and The Randy Shaver Community Cancer Fund. JRL is supported by NIH MSTP grant T32 GM008244 and the American Society of Hematology (ASH) Medical Student Minority Award. MF is supported by Department of Defense Award W81XWH-20-1-0659. JSM is supported by NCI grants R35 CA283892 and P01 CA111412. ESA is partially supported by NCI grant P30 CA077598.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets analyzed during the current study are not publicly available but can be made available upon reasonable request. The deidentified sequencing data are owned by Caris Life Sciences, and qualified researchers can apply for access by contacting Caris Life Sciences and signing a data usage agreement.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par30">Nicholas Zorko reports paid travel from Caris Life Sciences and Telix Pharmaceuticals. Andrew Elliott, Milan Radovich, George Sledge, and Chadhi Nabhan are employees of Caris Life Sciences. Yousef Zakharia reports personal fees (Advisory Board) from Bristol Myers Squibb, Janssen, Eisai, Exelixis, Genzyme Corporation, Pfizer. Vivek Narayan reports grants from Janssen, Merck, Regeneron, Pfizer, and Bristol Myers Squibb; and personal fees from Janssen, Merck, Regeneron, Pfizer, Exelixis, AstraZeneca, Myovant, and Bristol Myers Squibb. Mark N. Stein serves in a consulting or advisory role for Bristol-Myers Squibb/Medarex; Exelixis; Exelixis; Janssen Oncology; Merck Sharp &#x00026; Dohme; Vaccitech; Xencor and receives research funding from Advaxis (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals; Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp &#x00026; Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Regeneron (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst). Kevin K. Zarrabi reports advising/consulting fees from Exelixis, Esai. Akash Patniak reports Consultancy/Advisory Board for Janssen, Exelixis, Jounce Therapeutics, BostonGene. Grant/Research support from BMS. Clinical Trial Support from BMS, Clovis Oncology, Progenics, Janssen, Laekna, Astrazeneca, Xencor, and Zenith. Honoraria from Exelixis, Janssen, Roche, Clovis Oncology, Merck, Prime, Curio. M.A. Bilen has acted as a paid consultant for and/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi and has received grants to his institution from Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome &#x00026; Company, AAA, Peloton Therapeutics, and Pfizer for work performed as outside of the current study. Elisabeth I. Heath &#x02013; Advisory/Consulting: Astellas, AstraZeneca, Bayer, Sanofi; Steering Committee: Janssen; Honararia/Paid Travel: Astellas, Bayer, Caris, Sanofi, Seattle Genetics; Speaker&#x02019;s Bureau: Sanofi; Research Support: Astellas, Arvinas, AstraZeneca, Bayer, BioXcel, Bristol-Myers Squibb, Calibr, Calithera, Caris, Corcept, Corvis, Daiichi Sankyo, Eisai, Exelixis, Five Prime, Fortis, GlaxoSmithKline, Gilead Sciences, Harpoon, Hoffman-La Roche, Infinity, iTeos, Janssen, Merck Sharp &#x00026; Dohme, Merck, Mirati, Modra, Novartis, Oncolys, Peloton, Pfizer, Pharmacyclics, POINT Biopharma, Seattle Genetics. Emmanuel S. Antonarakis reports grants and personal fees from Janssen, Sanofi, Bayer, Bristol Myers Squibb, Curium, Novartis, Merck, Pfizer, AstraZeneca, Clovis, and Orion; and personal fees from Astellas, Amgen, Blue Earth, Exact Sciences, Invitae, Eli Lilly, and Foundation Medicine; in addition, he has an issued patent for an AR-V7 biomarker technology that is licensed to Qiagen. The remaining authors have no relevant discolsures or conflicts of interest to declare.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>H-R</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Ponnazhagan</surname><given-names>S</given-names></name></person-group><article-title>Revisiting immunotherapy: a focus on prostate cancer</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><fpage>1615</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-2948</pub-id><pub-id pub-id-type="pmid">32066566</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Cha H-R, Lee JH, Ponnazhagan S. Revisiting immunotherapy: a focus on prostate cancer. Cancer Res. 2020;80:1615&#x02013;23.<pub-id pub-id-type="pmid">32066566</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Dorff</surname><given-names>TB</given-names></name><name><surname>Narayan</surname><given-names>V</given-names></name><name><surname>Forman</surname><given-names>SJ</given-names></name><name><surname>Zang</surname><given-names>PD</given-names></name><name><surname>Fraietta</surname><given-names>JA</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Novel redirected T&#x02013;cell immunotherapies for advanced prostate cancer</article-title><source>Clin Cancer Res</source><year>2021</year><volume>28</volume><fpage>576</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-1483</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Dorff TB, Narayan V, Forman SJ, Zang PD, Fraietta JA, June CH, et al. Novel redirected T&#x02013;cell immunotherapies for advanced prostate cancer. Clin Cancer Res. 2021;28:576&#x02013;84.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Antonarakis</surname><given-names>ES</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Goh</surname><given-names>JC</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>JL</given-names></name><name><surname>Mehra</surname><given-names>N</given-names></name><etal/></person-group><article-title>Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial</article-title><source>J Clin Oncol</source><year>2023</year><volume>41</volume><fpage>3839</fpage><pub-id pub-id-type="doi">10.1200/JCO.23.00233</pub-id><pub-id pub-id-type="pmid">37290035</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, et al. Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial. J Clin Oncol. 2023;41:3839.<pub-id pub-id-type="pmid">37290035</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Shore</surname><given-names>ND</given-names></name><name><surname>Berger</surname><given-names>ER</given-names></name><name><surname>Small</surname><given-names>EJ</given-names></name><name><surname>Penson</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Sipuleucel-T immunotherapy for castration-resistant prostate cancer</article-title><source>N. Engl J Med</source><year>2010</year><volume>363</volume><fpage>411</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1001294</pub-id><pub-id pub-id-type="pmid">20818862</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl J Med. 2010;363:411&#x02013;22.<pub-id pub-id-type="pmid">20818862</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>A</given-names></name><name><surname>Massard</surname><given-names>C</given-names></name><name><surname>Ott</surname><given-names>P</given-names></name><name><surname>Haas</surname><given-names>N</given-names></name><name><surname>Lopez</surname><given-names>J</given-names></name><name><surname>Ejadi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study</article-title><source>Ann Oncol</source><year>2018</year><volume>29</volume><fpage>1807</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy232</pub-id><pub-id pub-id-type="pmid">29992241</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Hansen A, Massard C, Ott P, Haas N, Lopez J, Ejadi S, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018;29:1807&#x02013;13.<pub-id pub-id-type="pmid">29992241</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Antonarakis</surname><given-names>ES</given-names></name><name><surname>Piulats</surname><given-names>JM</given-names></name><name><surname>Gross-Goupil</surname><given-names>M</given-names></name><name><surname>Goh</surname><given-names>J</given-names></name><name><surname>Ojamaa</surname><given-names>K</given-names></name><name><surname>Hoimes</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><fpage>395</fpage><pub-id pub-id-type="doi">10.1200/JCO.19.01638</pub-id><pub-id pub-id-type="pmid">31774688</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395.<pub-id pub-id-type="pmid">31774688</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Shenderov</surname><given-names>E</given-names></name><name><surname>Boudadi</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Sullivan</surname><given-names>R</given-names></name><name><surname>Jordan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial</article-title><source>Prostate</source><year>2021</year><volume>81</volume><fpage>326</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1002/pros.24110</pub-id><pub-id pub-id-type="pmid">33636027</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Shenderov E, Boudadi K, Fu W, Wang H, Sullivan R, Jordan A, et al. Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial. Prostate. 2021;81:326&#x02013;38.<pub-id pub-id-type="pmid">33636027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, et al. Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). J Clin Oncol. 2019;37. 10.1200/JCO.2019.37.7_suppl.142</mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Pachynski</surname><given-names>RK</given-names></name><name><surname>Retz</surname><given-names>M</given-names></name><name><surname>Goh</surname><given-names>JC</given-names></name><name><surname>Burotto</surname><given-names>M</given-names></name><name><surname>Gravis</surname><given-names>G</given-names></name><name><surname>Castellano</surname><given-names>D</given-names></name><etal/></person-group><article-title>CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC)</article-title><source>J Clin Oncol</source><year>2021</year><volume>39</volume><fpage>5044</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1200/JCO.2021.39.15_suppl.5044</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Pachynski RK, Retz M, Goh JC, Burotto M, Gravis G, Castellano D, et al. CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2021;39:5044&#x02013;44.</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Fizazi K, Gonz&#x000e1;lez Mella P, Castellano D, Minatta JN, Rezazadeh A, Shaffer DR, et al. CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naive metastatic castration-resistant prostate cancer. Am Soc Clin Oncol. 2021;39. 10.1200/JCO.2021.39.6_suppl.12</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Evan</surname><given-names>YY</given-names></name><name><surname>Kolinsky</surname><given-names>MP</given-names></name><name><surname>Berry</surname><given-names>WR</given-names></name><name><surname>Retz</surname><given-names>M</given-names></name><name><surname>Mourey</surname><given-names>L</given-names></name><name><surname>Piulats</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort B study</article-title><source>Eur Urol</source><year>2022</year><volume>82</volume><fpage>22</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2022.02.023</pub-id><pub-id pub-id-type="pmid">35397952</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Evan YY, Kolinsky MP, Berry WR, Retz M, Mourey L, Piulats JM, et al. Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort B study. Eur Urol. 2022;82:22&#x02013;30.<pub-id pub-id-type="pmid">35397952</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Zarrabi</surname><given-names>KK</given-names></name><name><surname>Narayan</surname><given-names>V</given-names></name><name><surname>Mille</surname><given-names>PJ</given-names></name><name><surname>Zibelman</surname><given-names>MR</given-names></name><name><surname>Miron</surname><given-names>B</given-names></name><name><surname>Bashir</surname><given-names>B</given-names></name><etal/></person-group><article-title>Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer</article-title><source>Ther Adv Urol</source><year>2023</year><volume>15</volume><fpage>17562872231182219</fpage><pub-id pub-id-type="doi">10.1177/17562872231182219</pub-id><pub-id pub-id-type="pmid">37359737</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Zarrabi KK, Narayan V, Mille PJ, Zibelman MR, Miron B, Bashir B, et al. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer. Ther Adv Urol. 2023;15:17562872231182219.<pub-id pub-id-type="pmid">37359737</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Zorko</surname><given-names>N</given-names></name><name><surname>Merino</surname><given-names>A</given-names></name><name><surname>Phung</surname><given-names>G</given-names></name><name><surname>Khaw</surname><given-names>M</given-names></name><name><surname>Howard</surname><given-names>P</given-names></name><etal/></person-group><article-title>755P B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells</article-title><source>Ann Oncol</source><year>2022</year><volume>33</volume><fpage>S889</fpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.07.881</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Miller J, Zorko N, Merino A, Phung G, Khaw M, Howard P, et al. 755P B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells. Ann Oncol. 2022;33:S889.</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Phung SK, Soignier Y, Zorko N, Nelson T, Walker J, Kennedy PP, et al. 1204 Enhancing NK cell function in the &#x02018;cold&#x02019;tumor microenvironment of prostate cancer with a novel tri-specific Killer Engager against prostate-specific membrane antigen (PSMA). J Immuno ther Cancer. 2022;10. 10.1136/jitc-2022-SITC2022.120.</mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Carneiro</surname><given-names>B</given-names></name><name><surname>Garmezy</surname><given-names>B</given-names></name><name><surname>Hamm</surname><given-names>JT</given-names></name><name><surname>Sanborn</surname><given-names>RE</given-names></name><name><surname>Wise-Draper</surname><given-names>T</given-names></name><name><surname>Khoueiry</surname><given-names>AE-</given-names></name><etal/></person-group><article-title>Abstract CT275: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors</article-title><source>Cancer Res</source><year>2023</year><volume>83</volume><fpage>CT275</fpage><lpage>CT</lpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2023-CT275</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Carneiro B, Garmezy B, Hamm JT, Sanborn RE, Wise-Draper T, Khoueiry AE-, et al. Abstract CT275: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors. Cancer Res. 2023;83:CT275&#x02013;CT.</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Zorko</surname><given-names>NA</given-names></name><name><surname>Ryan</surname><given-names>CJ</given-names></name></person-group><article-title>Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?</article-title><source>Prostate Cancer P D</source><year>2021</year><volume>24</volume><fpage>986</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1038/s41391-021-00381-w</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Zorko NA, Ryan CJ. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs? Prostate Cancer P D. 2021;24:986&#x02013;96.</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Kannan</surname><given-names>GS</given-names></name><name><surname>Aquino-Lopez</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>DA</given-names></name></person-group><article-title>Natural killer cells in malignant hematology: a primer for the non-immunologist</article-title><source>Blood Rev</source><year>2017</year><volume>31</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.blre.2016.08.007</pub-id><pub-id pub-id-type="pmid">27665023</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Kannan GS, Aquino-Lopez A, Lee DA. Natural killer cells in malignant hematology: a primer for the non-immunologist. Blood Rev. 2017;31:1&#x02013;10.<pub-id pub-id-type="pmid">27665023</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Bj&#x000f6;rkstr&#x000f6;m</surname><given-names>NK</given-names></name><name><surname>Ljunggren</surname><given-names>H-G</given-names></name><name><surname>Sandberg</surname><given-names>JK</given-names></name></person-group><article-title>CD56 negative NK cells: origin, function, and role in chronic viral disease</article-title><source>Trends Immunol</source><year>2010</year><volume>31</volume><fpage>401</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.it.2010.08.003</pub-id><pub-id pub-id-type="pmid">20829113</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Bj&#x000f6;rkstr&#x000f6;m NK, Ljunggren H-G, Sandberg JK. CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends Immunol. 2010;31:401&#x02013;6.<pub-id pub-id-type="pmid">20829113</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Barrow</surname><given-names>AD</given-names></name><name><surname>Martin</surname><given-names>CJ</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><article-title>The natural cytotoxicity receptors in health and disease</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>909</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00909</pub-id><pub-id pub-id-type="pmid">31134055</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Barrow AD, Martin CJ, Colonna M. The natural cytotoxicity receptors in health and disease. Front Immunol. 2019;10:909.<pub-id pub-id-type="pmid">31134055</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Tomasello</surname><given-names>E</given-names></name><name><surname>Baratin</surname><given-names>M</given-names></name><name><surname>Walzer</surname><given-names>T</given-names></name><name><surname>Ugolini</surname><given-names>S</given-names></name></person-group><article-title>Functions of natural killer cells</article-title><source>Nat Immunol</source><year>2008</year><volume>9</volume><fpage>503</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/ni1582</pub-id><pub-id pub-id-type="pmid">18425107</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503&#x02013;10.<pub-id pub-id-type="pmid">18425107</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Marin</surname><given-names>D</given-names></name><name><surname>Banerjee</surname><given-names>P</given-names></name><name><surname>Macapinlac</surname><given-names>HA</given-names></name><name><surname>Thompson</surname><given-names>P</given-names></name><name><surname>Basar</surname><given-names>R</given-names></name><etal/></person-group><article-title>Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors</article-title><source>N. Engl J Med</source><year>2020</year><volume>382</volume><fpage>545</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1910607</pub-id><pub-id pub-id-type="pmid">32023374</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl J Med. 2020;382:545&#x02013;53.<pub-id pub-id-type="pmid">32023374</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>G</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Ham</surname><given-names>JD</given-names></name><name><surname>Rizwan</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>CAR-NK cells: a promising cellular immunotherapy for cancer</article-title><source>EBioMedicine</source><year>2020</year><volume>59</volume><fpage>102975</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102975</pub-id><pub-id pub-id-type="pmid">32853984</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.<pub-id pub-id-type="pmid">32853984</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Romain</surname><given-names>G</given-names></name><name><surname>Senyukov</surname><given-names>V</given-names></name><name><surname>Rey-Villamizar</surname><given-names>N</given-names></name><name><surname>Merouane</surname><given-names>A</given-names></name><name><surname>Kelton</surname><given-names>W</given-names></name><name><surname>Liadi</surname><given-names>I</given-names></name><etal/></person-group><article-title>Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells</article-title><source>Blood, J Am Soc Hematol</source><year>2014</year><volume>124</volume><fpage>3241</fpage><lpage>9</lpage></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Romain G, Senyukov V, Rey-Villamizar N, Merouane A, Kelton W, Liadi I, et al. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood, J Am Soc Hematol. 2014;124:3241&#x02013;9.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Berrien-Elliott</surname><given-names>MM</given-names></name><name><surname>Jacobs</surname><given-names>MT</given-names></name><name><surname>Fehniger</surname><given-names>TA</given-names></name></person-group><article-title>Allogeneic natural killer cell therapy</article-title><source>Blood</source><year>2023</year><volume>141</volume><fpage>856</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1182/blood.2022016200</pub-id><pub-id pub-id-type="pmid">36416736</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023;141:856&#x02013;68.<pub-id pub-id-type="pmid">36416736</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>JA</given-names></name><name><surname>Miller</surname><given-names>JS</given-names></name></person-group><article-title>Exploring the NK cell platform for cancer immunotherapy</article-title><source>Nat Rev Clin Oncol</source><year>2021</year><volume>18</volume><fpage>85</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-0426-7</pub-id><pub-id pub-id-type="pmid">32934330</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85&#x02013;100.<pub-id pub-id-type="pmid">32934330</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>W-Q</given-names></name></person-group><article-title>The evolving role of immune cells in prostate cancer</article-title><source>Cancer Lett</source><year>2022</year><volume>525</volume><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2021.10.027</pub-id><pub-id pub-id-type="pmid">34715253</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Wang C, Zhang Y, Gao W-Q. The evolving role of immune cells in prostate cancer. Cancer Lett. 2022;525:9&#x02013;21.<pub-id pub-id-type="pmid">34715253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Nazha</surname><given-names>B</given-names></name><name><surname>Zhuang</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>JT</given-names></name><name><surname>Magee</surname><given-names>D</given-names></name><name><surname>Carthon</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers</article-title><source>Cancer</source><year>2023</year><volume>129</volume><fpage>3884</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1002/cncr.34982</pub-id><pub-id pub-id-type="pmid">37565840</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Nazha B, Zhuang T, Wu S, Brown JT, Magee D, Carthon BC, et al. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers. Cancer. 2023;129:3884&#x02013;93.<pub-id pub-id-type="pmid">37565840</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Testing Menu [Internet]. Caris Life Sciences. 2024 [cited 2024 Jan 2]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.carislifesciences.com/products-and-services/molecular-profiling/testing-menu/">https://www.carislifesciences.com/products-and-services/molecular-profiling/testing-menu/</ext-link></mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Finotello</surname><given-names>F</given-names></name><name><surname>Mayer</surname><given-names>C</given-names></name><name><surname>Plattner</surname><given-names>C</given-names></name><name><surname>Laschober</surname><given-names>G</given-names></name><name><surname>Rieder</surname><given-names>D</given-names></name><name><surname>Hackl</surname><given-names>H</given-names></name><etal/></person-group><article-title>Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data</article-title><source>Genome Med</source><year>2019</year><volume>11</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s13073-019-0638-6</pub-id><pub-id pub-id-type="pmid">31126321</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019;11:34.<pub-id pub-id-type="pmid">31126321</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Abida</surname><given-names>W</given-names></name><name><surname>Cyrta</surname><given-names>J</given-names></name><name><surname>Heller</surname><given-names>G</given-names></name><name><surname>Prandi</surname><given-names>D</given-names></name><name><surname>Armenia</surname><given-names>J</given-names></name><name><surname>Coleman</surname><given-names>I</given-names></name><etal/></person-group><article-title>Genomic correlates of clinical outcome in advanced prostate cancer</article-title><source>Proc Natl Acad Sci USA</source><year>2019</year><volume>116</volume><fpage>11428</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1073/pnas.1902651116</pub-id><pub-id pub-id-type="pmid">31061129</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428&#x02013;36.<pub-id pub-id-type="pmid">31061129</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Wu</surname><given-names>YM</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Lonigro</surname><given-names>RJ</given-names></name><name><surname>Mosquera</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Integrative clinical genomics of advanced prostate cancer</article-title><source>Cell</source><year>2015</year><volume>161</volume><fpage>1215</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.001</pub-id><pub-id pub-id-type="pmid">26000489</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215&#x02013;28.<pub-id pub-id-type="pmid">26000489</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Quigley</surname><given-names>DA</given-names></name><name><surname>Dang</surname><given-names>HX</given-names></name><name><surname>Zhao</surname><given-names>SG</given-names></name><name><surname>Lloyd</surname><given-names>P</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Alumkal</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Genomic hallmarks and structural variation in metastatic prostate cancer</article-title><source>Cell</source><year>2018</year><volume>174</volume><fpage>758</fpage><lpage>69 e9</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.06.039</pub-id><pub-id pub-id-type="pmid">30033370</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell. 2018;174:758&#x02013;69 e9.<pub-id pub-id-type="pmid">30033370</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc Natl Acad Sci</source><year>2005</year><volume>102</volume><fpage>15545</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545&#x02013;50.<pub-id pub-id-type="pmid">16199517</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>C&#x000f3;zar</surname><given-names>B</given-names></name><name><surname>Greppi</surname><given-names>M</given-names></name><name><surname>Carpentier</surname><given-names>S</given-names></name><name><surname>Narni-Mancinelli</surname><given-names>E</given-names></name><name><surname>Chiossone</surname><given-names>L</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name></person-group><article-title>Tumor-infiltrating natural killer cells</article-title><source>Cancer Discov</source><year>2021</year><volume>11</volume><fpage>34</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0655</pub-id><pub-id pub-id-type="pmid">33277307</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">C&#x000f3;zar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E. Tumor-infiltrating natural killer cells. Cancer Discov. 2021;11:34&#x02013;44.<pub-id pub-id-type="pmid">33277307</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Zeng</surname><given-names>F</given-names></name><etal/></person-group><article-title>The landscape of immune cells infiltrating in prostate cancer</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>517637</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.517637</pub-id><pub-id pub-id-type="pmid">33194581</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Wu Z, Chen H, Luo W, Zhang H, Li G, Zeng F, et al. The landscape of immune cells infiltrating in prostate cancer. Front Oncol. 2020;10:517637.<pub-id pub-id-type="pmid">33194581</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lichtenberg</surname><given-names>T</given-names></name><name><surname>Hoadley</surname><given-names>KA</given-names></name><name><surname>Poisson</surname><given-names>LM</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><etal/></person-group><article-title>An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics</article-title><source>Cell</source><year>2018</year><volume>173</volume><fpage>400</fpage><lpage>16.e11</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.02.052</pub-id><pub-id pub-id-type="pmid">29625055</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 2018;173:400&#x02013;16.e11.<pub-id pub-id-type="pmid">29625055</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Dal Pra</surname><given-names>A</given-names></name><name><surname>Lalonde</surname><given-names>E</given-names></name><name><surname>Sykes</surname><given-names>J</given-names></name><name><surname>Warde</surname><given-names>F</given-names></name><name><surname>Ishkanian</surname><given-names>A</given-names></name><name><surname>Meng</surname><given-names>A</given-names></name><etal/></person-group><article-title>TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>5202</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1049</pub-id><pub-id pub-id-type="pmid">23918607</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, et al. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res. 2013;19:5202&#x02013;9.<pub-id pub-id-type="pmid">23918607</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Kulda</surname><given-names>V</given-names></name><name><surname>Topolcan</surname><given-names>O</given-names></name><name><surname>Kucera</surname><given-names>R</given-names></name><name><surname>Kripnerova</surname><given-names>M</given-names></name><name><surname>Srbecka</surname><given-names>K</given-names></name><name><surname>Hora</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prognostic significance of <italic>TMPRSS2-ERG</italic> fusion gene in prostate cancer</article-title><source>Anticancer Res</source><year>2016</year><volume>36</volume><fpage>4787</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.21873/anticanres.11037</pub-id><pub-id pub-id-type="pmid">27630329</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, et al. Prognostic significance of <italic>TMPRSS2-ERG</italic> fusion gene in prostate cancer. Anticancer Res. 2016;36:4787&#x02013;93.<pub-id pub-id-type="pmid">27630329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>R</given-names></name><name><surname>Sugar</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Klotz</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Expression of the TMPRSS2: ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer</article-title><source>Br J cancer</source><year>2007</year><volume>97</volume><fpage>1690</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604054</pub-id><pub-id pub-id-type="pmid">17971772</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Nam R, Sugar L, Yang W, Srivastava S, Klotz L, Yang L, et al. Expression of the TMPRSS2: ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J cancer. 2007;97:1690&#x02013;5.<pub-id pub-id-type="pmid">17971772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Semaan</surname><given-names>L</given-names></name><name><surname>Mander</surname><given-names>N</given-names></name><name><surname>Cher</surname><given-names>ML</given-names></name><name><surname>Chinni</surname><given-names>SR</given-names></name></person-group><article-title>TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model</article-title><source>BMC cancer</source><year>2019</year><volume>19</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12885-019-6185-0</pub-id><pub-id pub-id-type="pmid">30606139</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Semaan L, Mander N, Cher ML, Chinni SR. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model. BMC cancer. 2019;19:1&#x02013;10.<pub-id pub-id-type="pmid">30606139</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Obradovic</surname><given-names>AZ</given-names></name><name><surname>Dallos</surname><given-names>MC</given-names></name><name><surname>Zahurak</surname><given-names>ML</given-names></name><name><surname>Partin</surname><given-names>AW</given-names></name><name><surname>Schaeffer</surname><given-names>EM</given-names></name><name><surname>Ross</surname><given-names>AE</given-names></name><etal/></person-group><article-title>T-Cell infiltration and adaptive treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer</article-title><source>Clin Cancer Res</source><year>2020</year><volume>26</volume><fpage>3182</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-3372</pub-id><pub-id pub-id-type="pmid">32173650</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Obradovic AZ, Dallos MC, Zahurak ML, Partin AW, Schaeffer EM, Ross AE, et al. T-Cell infiltration and adaptive treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer. Clin Cancer Res. 2020;26:3182&#x02013;92.<pub-id pub-id-type="pmid">32173650</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Erlandsson</surname><given-names>A</given-names></name><name><surname>Carlsson</surname><given-names>J</given-names></name><name><surname>Lundholm</surname><given-names>M</given-names></name><name><surname>F&#x000e4;lt</surname><given-names>A</given-names></name><name><surname>Andersson</surname><given-names>SO</given-names></name><name><surname>Andr&#x000e9;n</surname><given-names>O</given-names></name><etal/></person-group><article-title>M2 macrophages and regulatory T cells in lethal prostate cancer</article-title><source>Prostate</source><year>2019</year><volume>79</volume><fpage>363</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/pros.23742</pub-id><pub-id pub-id-type="pmid">30500076</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Erlandsson A, Carlsson J, Lundholm M, F&#x000e4;lt A, Andersson SO, Andr&#x000e9;n O, et al. M2 macrophages and regulatory T cells in lethal prostate cancer. Prostate. 2019;79:363&#x02013;9.<pub-id pub-id-type="pmid">30500076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Spiegel</surname><given-names>A</given-names></name><name><surname>Brooks</surname><given-names>MW</given-names></name><name><surname>Houshyar</surname><given-names>S</given-names></name><name><surname>Reinhardt</surname><given-names>F</given-names></name><name><surname>Ardolino</surname><given-names>M</given-names></name><name><surname>Fessler</surname><given-names>E</given-names></name><etal/></person-group><article-title>Neutrophils suppress intraluminal NK cell&#x02013;mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells</article-title><source>Cancer Discov</source><year>2016</year><volume>6</volume><fpage>630</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-1157</pub-id><pub-id pub-id-type="pmid">27072748</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Spiegel A, Brooks MW, Houshyar S, Reinhardt F, Ardolino M, Fessler E, et al. Neutrophils suppress intraluminal NK cell&#x02013;mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells. Cancer Discov. 2016;6:630&#x02013;49.<pub-id pub-id-type="pmid">27072748</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>MJ</given-names></name></person-group><article-title>Role of chemokines in the biology of natural killer cells</article-title><source>J Leukoc Biol</source><year>2002</year><volume>71</volume><fpage>173</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1189/jlb.71.2.173</pub-id><pub-id pub-id-type="pmid">11818437</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002;71:173&#x02013;83.<pub-id pub-id-type="pmid">11818437</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Susek</surname><given-names>KH</given-names></name><name><surname>Karvouni</surname><given-names>M</given-names></name><name><surname>Alici</surname><given-names>E</given-names></name><name><surname>Lundqvist</surname><given-names>A</given-names></name></person-group><article-title>The role of CXC chemokine receptors 1&#x02013;4 on immune cells in the tumor microenvironment</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>2159</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02159</pub-id><pub-id pub-id-type="pmid">30319622</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Susek KH, Karvouni M, Alici E, Lundqvist A. The role of CXC chemokine receptors 1&#x02013;4 on immune cells in the tumor microenvironment. Front Immunol. 2018;9:2159.<pub-id pub-id-type="pmid">30319622</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Tuong</surname><given-names>ZK</given-names></name><name><surname>Loudon</surname><given-names>KW</given-names></name><name><surname>Berry</surname><given-names>B</given-names></name><name><surname>Richoz</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><etal/></person-group><article-title>Resolving the immune landscape of human prostate at a single-cell level in health and cancer</article-title><source>Cell Rep</source><year>2021</year><volume>37</volume><fpage>110132</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.110132</pub-id><pub-id pub-id-type="pmid">34936871</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Tuong ZK, Loudon KW, Berry B, Richoz N, Jones J, Tan X, et al. Resolving the immune landscape of human prostate at a single-cell level in health and cancer. Cell Rep. 2021;37:110132.<pub-id pub-id-type="pmid">34936871</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Hirz</surname><given-names>T</given-names></name><name><surname>Mei</surname><given-names>S</given-names></name><name><surname>Sarkar</surname><given-names>H</given-names></name><name><surname>Kfoury</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Verhoeven</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>663</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-36325-2</pub-id><pub-id pub-id-type="pmid">36750562</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663.<pub-id pub-id-type="pmid">36750562</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>AM</given-names></name><name><surname>Liu</surname><given-names>CL</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name><name><surname>Gentles</surname><given-names>AJ</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Robust enumeration of cell subsets from tissue expression profiles</article-title><source>Nat methods</source><year>2015</year><volume>12</volume><fpage>453</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3337</pub-id><pub-id pub-id-type="pmid">25822800</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat methods. 2015;12:453&#x02013;7.<pub-id pub-id-type="pmid">25822800</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Sturm</surname><given-names>G</given-names></name><name><surname>Finotello</surname><given-names>F</given-names></name><name><surname>Petitprez</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>JD</given-names></name><name><surname>Baumbach</surname><given-names>J</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology</article-title><source>Bioinformatics</source><year>2019</year><volume>35</volume><fpage>i436</fpage><lpage>i45</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btz363</pub-id><pub-id pub-id-type="pmid">31510660</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Sturm G, Finotello F, Petitprez F, Zhang JD, Baumbach J, Fridman WH, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019;35:i436&#x02013;i45.<pub-id pub-id-type="pmid">31510660</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>